Breaking News, Financial News

Financial Report: Covance 1Q

Early development revenues were $192.5 million (-5%). Late-stage development revenues were up 18% to $248.7 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Covance 1Q 1Q Revenues: $468.4 million (+8%) 1Q Earnings: $40.3 million (-18%) Comments: Early development revenues were $192.5 million (-5%). Late-stage development revenues were up 18% to $248.7 million. Backlog at March 31, 2009 was up 54% to $4.4 billion. Adjusted net orders (orders adjusted for dedicated capacity contracts) were $589 million in the quarter....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters